MX2022003871A - Composiciones inmunogénicas. - Google Patents

Composiciones inmunogénicas.

Info

Publication number
MX2022003871A
MX2022003871A MX2022003871A MX2022003871A MX2022003871A MX 2022003871 A MX2022003871 A MX 2022003871A MX 2022003871 A MX2022003871 A MX 2022003871A MX 2022003871 A MX2022003871 A MX 2022003871A MX 2022003871 A MX2022003871 A MX 2022003871A
Authority
MX
Mexico
Prior art keywords
immunogenic compositions
field
vaccines
bacterium
prevention
Prior art date
Application number
MX2022003871A
Other languages
English (en)
Inventor
Nathalie Isabelle Devos
Steven Clement Sijmons
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2022003871A publication Critical patent/MX2022003871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención se relaciona con cepas bacterianas, en particular para su uso en el campo de las vacunas, en particular en el campo de la prevención o tratamiento de infecciones provocadas por la bacteria del género Bordetella.
MX2022003871A 2019-10-01 2020-09-30 Composiciones inmunogénicas. MX2022003871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19200878.7A EP3799884A1 (en) 2019-10-01 2019-10-01 Immunogenic compositions
PCT/EP2020/077416 WO2021064050A1 (en) 2019-10-01 2020-09-30 Immunogenic compositions

Publications (1)

Publication Number Publication Date
MX2022003871A true MX2022003871A (es) 2022-06-02

Family

ID=68136165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003871A MX2022003871A (es) 2019-10-01 2020-09-30 Composiciones inmunogénicas.

Country Status (11)

Country Link
US (1) US20220339277A1 (es)
EP (2) EP3799884A1 (es)
JP (1) JP2022550560A (es)
KR (1) KR20220070279A (es)
CN (1) CN114502193A (es)
AU (1) AU2020358775A1 (es)
BR (1) BR112022005345A2 (es)
CA (1) CA3156017A1 (es)
IL (1) IL291559A (es)
MX (1) MX2022003871A (es)
WO (1) WO2021064050A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5388E (fr) 1905-06-08 1906-03-27 Jean Eugene Gabillon Radiateur à grand pouvoir refroidissant pour automobiles
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
ES2078258T3 (es) 1989-04-28 1995-12-16 Sclavo Spa Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
RU2118164C1 (ru) 1992-06-25 1998-08-27 Смитклайн Бичам Байолоджикалс, С.А. Вакцинная композиция, обладающая свойством вызывать цитолитический т-клеточный ответ у млекопитающих, способ получения цитолитического т-клеточного ответа in vivo, способ получения вакцины
ES2210262T3 (es) 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69637597D1 (de) 1995-06-07 2008-08-21 Glaxosmithkline Biolog Sa Vakzine mit einem Polysaccharide Antigen-Trägerprotein Konjugat und freiem Trägerprotein
US6558677B2 (en) 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US7011836B1 (en) * 1997-08-21 2006-03-14 De Staat Der Nederlanden, Vertenwoordigd Door De Minister Van Welzijn, Volksgezondheil En Cultuur Mutants of gram negative mucosal bacteria and application thereof in vaccines
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
KR100865706B1 (ko) 2000-09-26 2008-10-28 이데라 파마슈티칼즈, 인코포레이티드 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2003050782A1 (fr) 2001-12-12 2003-06-19 Hogakukan Co., Ltd. Systeme de definition d'exercices
GB0202901D0 (en) 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
WO2013130779A1 (en) 2012-02-28 2013-09-06 The Board Of Regents Of The University Of Texas System Synthetic lipid biology for combinatorial engineering of endotoxin
PL404247A1 (pl) * 2013-06-07 2014-12-08 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
US10420833B2 (en) 2014-05-19 2019-09-24 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
MX2019001167A (es) 2016-07-28 2019-09-16 Max Planck Gesellschaft Derivados sinteticos estables de poliribosilribitolfosfato resistentes a la hidrolisis como vacunas contra haemophilus influenzae tipo b.
WO2018167061A1 (en) 2017-03-13 2018-09-20 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Bordetella vaccines comprising lps with reduced reactogenicity
AU2018379236A1 (en) * 2017-12-04 2020-06-18 Intravacc B.V. An improved process for producing outer membrane vesicles

Also Published As

Publication number Publication date
WO2021064050A1 (en) 2021-04-08
JP2022550560A (ja) 2022-12-02
KR20220070279A (ko) 2022-05-30
EP3799884A1 (en) 2021-04-07
BR112022005345A2 (pt) 2023-04-25
IL291559A (en) 2022-05-01
AU2020358775A1 (en) 2022-04-14
CA3156017A1 (en) 2021-04-08
EP4038090A1 (en) 2022-08-10
CN114502193A (zh) 2022-05-13
US20220339277A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
EA201990566A1 (ru) Композиции, содержащие бактериальные штаммы
SA517390513B1 (ar) تركيبات تشتمل على سلالات بكتيرية
WO2020120714A8 (en) Compositions comprising bacterial strains
EP4282489A3 (en) Treatment of clostridium difficile infection
MX2020012061A (es) Composiciones que comprenden cepas bacterianas.
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
AR106800A1 (es) Composiciones que comprenden cepas bacterianas
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
MX2013000369A (es) Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
MX342443B (es) Vacunas que comprenden cepas de mycoplasma bovis atenuadas y metodo para la atenuacion.
MX2021002719A (es) Cannabinoides para el tratamiento de infecciones grampositivas incluidas cepas bacterianas resistentes a antibióticos.
MX2010003719A (es) Vacuna de mycoplasma bovis y metodos de uso de la misma.
MX2019001978A (es) Compuestos antibioticos.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12016501988A1 (en) Antibacterial compounds
MX2022003871A (es) Composiciones inmunogénicas.
MX2017012073A (es) Compuestos de minociclina para biodefensas.
ZA202002093B (en) Antibacterial compounds
MX2017009094A (es) Derivado de polimixina y usos del mismo.
AU2016248452A8 (en) Bordetella pertussis immunogenic vaccine compositions
PH12018500358A1 (en) Compounds for use in an antibacterial applications
EP4241851A3 (en) Immunogenic compositions
MX2018011095A (es) Compuestos de carbapenem.
NZ737820A (en) Mannose derivatives for treating bacterial infections